Abstracts tagged "prognostic factors"

Abstract Number: 0384 • ACR Convergence 2020
Serum Neutrophil Count Predicts Progression of Interstitial Lung Disease and Mortality in Patients with Systemic Sclerosis Related Interstitial Lung Disease
Nancy Wareing¹, Ning Li², Elizabeth Volkmann³, Marka Lyons⁴, Michael Roth², Donald Tashkin² and Shervin Assassi¹, ¹University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ²University of California, Los Angeles, Los Angeles, ³University of California, Los Angeles, Los Angeles, CA, ⁴University of Texas Houston, McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX
Background/Purpose: Systemic sclerosis (SSc) patients have a prominent neutrophil gene expression signature. However, investigations into the pathophysiologic role of neutrophils in SSc are lacking. This…
Abstract Number: 1581 • ACR Convergence 2020
Neutrophil to Lymphocyte Ratio as a Predictor of Immune-Related Adverse Events in CTLA-4 Treated Patients: A Retrospective Review
Michael Cunningham¹, Carolina Alvarez², Shruti Saxena Beem³, Todd Schwartz⁴ and Rumey Ishizawar⁵, ¹UNC Hospitals, Durham, NC, ²University of North Carolina at Chapel Hill Thurston Arthritis Research Center, Miami, FL, ³University of North Carolina at Chapel Hill, Chapel Hill, ⁴University of North Carolina-Chapel Hill, Chapel Hill, NC, ⁵University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Immune checkpoint inhibitors (ICIs) target checkpoint proteins PD-1/PD-L1 and CTLA-4 to activate and enhance the cytotoxic effects of T lymphocytes against tumor cells [1-2].…
Abstract Number: 0388 • ACR Convergence 2020
Factors Prognostic of Greater Decline in Forced Vital Capacity in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Data from the Placebo Group of the SENSCIS Trial
Masataka Kuwana¹, Shervin Assassi², Jérôme Avouac³, Rachel Hoyles⁴, Janet Pope⁵, Vanessa Smith⁶, Corinna Miede⁷, Emmanuelle Clerisme-Beaty⁸, Margarida Alves⁹ and Oliver Distler¹⁰, ¹Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Tokyo, Japan, ²University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ³Department of Rheumatology - Hôpital Cochin, Assistance Publique - Hôpitaux de Paris, Paris Descartes University, France, Paris, France, ⁴Department of Respiratory Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, Oxford, United Kingdom, ⁵Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ⁶Department of Rheumatology, Ghent University Hospital, Department of Internal Medicine, VIB Inflammation Research Centre Ghent University, Ghent, Belgium, ⁷mainanalytics GmbH, Sulzbach (Taunus), Germany, Sulzbach (Taunus), Germany, ⁸Boehringer Ingelheim International GmbH, Ingelheim, Germany, Ingelheim, Germany, ⁹Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ¹⁰Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Zurich, Switzerland
Background/Purpose: The progression of SSc-ILD is variable and unpredictable. However, observational studies have identified patient characteristics that may be prognostic of a greater rate of…
Abstract Number: 1717 • ACR Convergence 2020
Impact of Treatments on Favorable Outcome over the First 10 Years of Disease in Early Rheumatoid Arthritis: Results from a WCE Model in the ESPOIR Cohort
Joanna Kedra¹, David Hajage¹, Alexandre Lafourcade¹, Bernard Combe², Maxime Dougados³ and Bruno Fautrel⁴, ¹Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique, UMR S1136, Paris, France, Paris, France, ²University of Montpellier, Montpellier, France, ³Department of Rheumatology, Hopital Cochin, Université de Paris, Paris, France, ⁴Sorbonne University, INSERM, IPLES; Pitié-Salpêtrière Hospital, Paris, Ile-de-France, France
Background/Purpose: Long-term observational studies on the prediction of favorable outcome (FO) in rheumatoid arthritis (RA) have mostly considered patients baseline characteristics and have rarely evaluated…
Abstract Number: 689 • 2019 ACR/ARP Annual Meeting
Patterns of High Disease Activity Status and Outcomes in Systemic Lupus Erythematosus
Alberta Hoi ¹, Hieu Nim ², Rachel Koelmeyer ², Ying Sun ³, Amy Kao ⁴, Oliver Guenther ³ and Eric Morand², ¹School of Clinical Sciences, Monash University, Meloburne, Victoria, Australia, ²Monash University, Melbourne, Victoria, Australia, ³Merck Healthcare KGaA, Darmstadt, Germany, ⁴EMD Serono Research & Development Institute, Inc., Billerica, MA
Background/Purpose: High Disease Activity Status (HDAS), defined as ever attainment of SLEDAI-2k of 10 or greater, may be a useful indicator of overall disease severity in…
Abstract Number: 2012 • 2019 ACR/ARP Annual Meeting
A Composite IFN-Based Signature Is Associated with a Filgotinib-Specific Clinical Response in bDMARD-Experienced Rheumatoid Arthritis Patients
Peter Taylor¹, Bryan Downie ², Emon Elboudwarej ³, Rachael Hawtin ³, Amer M. Mirza ³ and Jinfeng Liu ³, ¹University of Oxford, Oxford, United Kingdom, ²Gilead Sciences, Inc., Foster Citty, CA, ³Gilead Sciences, Inc., Foster City, CA
Background/Purpose: Filgotinib (FIL), an oral, selective, Janus Kinase 1 (JAK1) inhibitor was effective in Phase 3 studies of active RA in patients (pts) with inadequate…
Abstract Number: 2326 • 2019 ACR/ARP Annual Meeting
Prognostic Markers for Preclinical Cardiovascular Disease in Rheumatoid Arthritis and Correlation with Disease Activity
Annelies Blanken¹, Rabia Agca ², Conny van der Laken ³ and Mike Nurmohamed ⁴, ¹Amsterdam Rheumatology and immunulogy Center location Reade, Amsterdam, Netherlands, ²Amsterdam Rheumatology and immunology Center location Reade, Amsterdam, Netherlands, ³Amsterdam Rheumatology and immunology Center location Amsterdam UMC location VU medical center, Amsterdam, Netherlands Antilles, ⁴Amsterdam Rheumatology and immunology Center location Reade and Amsterdam UMC location VU medical center, Amsterdam, Netherlands
Background/Purpose: Patients with rheumatoid arthritis (RA) have an elevated cardiovascular (CV) disease risk, explained both by an increased prevalence of traditional CV risk factors and…
Abstract Number: 2625 • 2019 ACR/ARP Annual Meeting
Predictors of Advanced Chronic Kidney Disease in Patients with ANCA Vasculitis and Renal Involvement
Gelsomina Alle¹, John Jaramillo Gallego ², Marina Scolnik ³, Valeria Scaglioni ², Martin Brom ⁴, Carlos Varela ⁵, Gustavo Greloni ⁵ and Enrique Soriano ⁶, ¹Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Ciudad Autónoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ²Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Ciudad Autónoma de Buenos Aires, Argentina, ³Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁴Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ⁵Nephrology Service, Hospital Italiano de Buenos Aires, Argentina, Ciudad Autónoma de Buenos Aires, Argentina, ⁶Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Buenos Aires, Buenos Aires, Argentina
Background/Purpose: The aim of this study was to evaluate the predictors of advanced chronic kidney disease (ACKD) in patients with Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis…
Abstract Number: 2913 • 2019 ACR/ARP Annual Meeting
Serum Interferon Score Predicts Clinical Outcome at 12 Months in Diffuse Cutaneous Systemic Sclerosis as Measured by Global Ranked Composite Score (GRCS) and Composite Response Index in SSc (CRISS)
Antonio Carriero ¹, Giuseppina Abignano ², MIchelle Hutchinson ³, Karri Ballard ⁴ and Francesco Del Galdo⁵, ¹University of Leeds, Leeds, England, United Kingdom, ²3Rheumatology Institute of Lucania (IReL) and University of Leeds, Leeds, United Kingdom, ³University of Leeds and LTHT NIHR Biomedical Research Centre, Leeds, England, United Kingdom, ⁴Myriad RBM, austin, TX, ⁵University of Leeds and LTHT NIHR Biomedical Research Centre, Leeds, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) is a highly heterogeneous disease orphan of effective disease modifying agents. The diffuse cutaneous clinical subset (dcSSc) is currently targeted in…
Abstract Number: 2781 • 2018 ACR/ARHP Annual Meeting
Long Term Follow-up Results of Takayasu Arteritis Cohort: A Tertiary-Single Center Study
Sema Kaymaz Tahra¹, Fatma Alibaz-Oner¹ and Haner Direskeneli², ¹Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ²Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: To assess the clinical characteristics and long term follow-up outcomes of patients with Takayasu’s arteritis (TAK) in a tertiary referral center. Methods: In this…
Abstract Number: 2936 • 2018 ACR/ARHP Annual Meeting
Esophageal Erosion Predicts Progression of Lung Disease in Patients with Systemic Sclerosis
Silvia Laura Bosello¹, Enrico De Lorenzis¹, Gerlando Natalello², Giovanni Battista Canestrari¹, Laura Gigante¹, Lucrezia Verardi¹, Ludovica Berardini³ and Elisa Gremese¹, ¹Division of Rheumatology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy, ²Division of Rhematology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy, ³Division of Respiratory Medicine, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in Systemic Sclerosis (SSc) but its pathogenesis is not fully understood. Esophageal disease is…
Abstract Number: 660 • 2018 ACR/ARHP Annual Meeting
Progression of Radiographic Sacroiliitis in Patients with Axial Spondyloarthritis from the Assessment of Spondyloarthritis International Society Cohort on Central Reading – Five-Year Data
Mikhail Protopopov¹, Fabian Proft¹, Alexandre Sepriano^2,3, Robert B.M. Landewé^4,5, Désirée van der Heijde², Joachim Sieper¹, Martin Rudwaleit^6,7 and Denis Poddubnyy^1,8, ¹Charité Universitätsmedizin Berlin, Berlin, Germany, ²Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal, ⁴Zuyderland Medical Center, Heerlen, Netherlands, ⁵Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands, ⁶Charité Universitätsmeidzin Berlin, Berlin, Germany, ⁷Rheumatology, Klinikum Bielefeld Rosenhöhe, Berlin, Germany, ⁸German Rheumatism Research Centre, Berlin, Germany
Background/Purpose: It is known that radiographic progression of sacroiliitis in axial spondyloarthritis (axSpA) is quite slow, with only few predictors of such progression identified. An…
Abstract Number: 863 • 2018 ACR/ARHP Annual Meeting
Combining Cardiac Magnetic Resonance and Right Heart Catheterization to Evaluate Right Ventricular Function for the Prognosis Prediction in Patients with Connective Tissue Diseases and Pulmonary Hypertension
Nobuya Abe¹, Masaru Kato², Hiroyuki Nakamura², Atsushi Noguchi², Yuichiro Fujieda², Kenji Oku², Toshiyuki Bohgaki², Olga Amengual², Shinsuke Yasuda² and Tatsuya Atsumi², ¹Department of Rheumatology, Endocrinology and Nephrology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Background/Purpose: Pulmonary arterial hypertension associated with connective tissue diseases (CTD-PAH), particularly PAH associated with systemic sclerosis (SSc-PAH), has a poor prognosis compared with other PAH.…
Abstract Number: 1502 • 2018 ACR/ARHP Annual Meeting
Predicting Response to Methotrexate Therapy in New-Onset RA: No Value of Adding Protein Biomarkers to Clinical Predictors
Xavier M Teitsma¹, Johannes W. G. Jacobs², Pascal HP de Jong³, JMW Hazes³, Angelique EAM Weel^3,4, Paco MJ Welsing¹, Attila Pethö-Schramm⁵, Michelle EA Borm⁶, Jacob van Laar¹, Johannes W. J. Bijlsma⁷ and Floris PJG Lafeber⁸, ¹Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, the Netherlands, Utrecht, Netherlands, ²Rheumatolgy & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ³Rheumatology, Erasmus Medical Center Rotterdam, Rotterdam, Netherlands, ⁴Rheumatology, Maastad Hospital, Rotterdam, Netherlands, ⁵F. Hoffmann-La Roche, Basel, Switzerland, ⁶Roche Nederland BV, Woerden, Netherlands, ⁷Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁸Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: We previously identified higher disease activity score assessing 28 joints (DAS28) at baseline, current smoking and no alcohol consumption as clinical predictors for inadequate…
Abstract Number: 1718 • 2018 ACR/ARHP Annual Meeting
Skin Gene Expression Profiling Predicts Longitudinal Modified Rodnan Skin Score Change
Chase Correia¹, Mary A. Carns², Kathleen Aren², Monique Hinchcliff³ and J. Matthew Mahoney⁴, ¹Rheumatology, Northwestern Feinberg School of Medicine, Chicago, IL, ²Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ³Rheumatology, Northwestern University, Chicago, IL, ⁴Neurological Sciences, University of Vermont College of Medicine, Burlington, VT
Background/Purpose: Systemic sclerosis (SSc) causes varying degrees of skin fibrosis with varying trajectory. Extent of skin involvement is measured by the modified Rodnan skin score…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].